PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2026/3 - Bial Portela / Ativos GSK
Acquired
Assets Glaxo Group Limited
Description
(i) Elebrato Ellipta, (ii) Laventair Ellipta, (iii) Revinty Ellipta, (iv) Trelegy Ellipta, (v) Anoro Ellipta and (vi) Relvar Ellipta are used in the treatment of chronic obstructive pulmonary disease; (iii) Revinty Ellipta and (vi) Relvar Ellipta are also used in the treatment of asthma.
Acquiring
BIAL - PORTELA & CA, S.A
Description
A pharmaceutical company whose main activities include research and development of new medicines, particularly in the areas of neuroscience and rare diseases, and the production, marketing and/or promotion of medicines, both from its own research and under license from international pharmaceutical companies.
Sector
Activity (NACE)
Applicable legislation
Notification thresholds
Type of merger
Cooperation with sector regulators
Status
Ongoing
Type of Investigation
AdC’s decision
Case description

The concentration operation consists of the acquisition, by BIAL – Portela & CA., S.A., (“Bial Portela”), of control over the GlaxoSmithKline branded medicines known as (i) Elebrato Ellipta, (ii) Laventair Ellipta, (iii) Revinty Ellipta, (iv) Trelegy Ellipta, (v) Anoro Ellipta and (vi) Relvar Ellipta (collectively, “GSK Assets”).
Timeline
2026-01-16
Bial Portela notifies the acquisition of control over a set of GSK assets
Click here to see your activities